QuidelOrtho Corporation QDEL
Set alert
As of Nov 2, 10:25 AM ET
- YTD
- -51.73%
- 1 year
- -48.92%
- Open
- 13.53
- Prev close
- 13.25
- Mkt cap
- 940.85M
- Vol
- 244.26K
- Avg vol
- 1.79M
- EPS
- -15.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.09
- High
- 13.77
- Forward P/E
- 10.22
- Beta
- 0.69
- Short ratio
- 10.38
- Inst. own
- 124.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 15.81
- 200-d avg
- 19.67
- 1y target
- 14.67
2Y chart
Events in this range
- Aug 5, 2025Earnings: 0.12; estimate 0.00153; surprise 7743.14%
- Nov 5, 2025Earnings: 0.8; estimate 0.51; surprise 56.86%
- Feb 11, 2026Earnings: 0.46; estimate 0.43; surprise 6.98%
- Feb 12, 2026Rating: Citigroup · Neutral → Neutral
- Apr 10, 2026Rating: UBS · Neutral → Neutral
- May 5, 2026Earnings: -0.04; estimate 0.37; surprise -110.81%
- May 6, 2026Rating: Citigroup · Neutral → Neutral
- May 7, 2026Downgrade: Jefferies · Buy → Hold
- Jul 1, 2026Rating: JP Morgan · Underweight → Underweight
- Jul 8, 2026Rating: Citigroup · Neutral → Neutral
- Aug 6, 2026Earnings: 0.13; estimate -0.04884; surprise 366.18%
Signals (95)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 55 minutes ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 18, 2026 | 1 month ago |
| RSI: Oversold | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 2, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 7, 2026 | 2 months ago |
| RSI: Oversold | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 17, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 29, 2026 | 4 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 30, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 20, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 30, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 27, 2026 | 7 months ago |
| RSI: Oversold | Mar 27, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 26, 2026 | 7 months ago |
| RSI: Oversold | Mar 9, 2026 | 7 months ago |
| RSI: Oversold | Feb 23, 2026 | 8 months ago |
| RSI: Oversold | Feb 17, 2026 | 8 months ago |
| SMA: Bearish | Feb 12, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 9 months ago |
| SMA: Bullish | Feb 4, 2026 | 9 months ago |
| SMA: Bullish | Feb 4, 2026 | 9 months ago |
| SMA: Bearish | Jan 27, 2026 | 9 months ago |
| SMA: Bearish | Jan 27, 2026 | 9 months ago |
| SMA: Bullish | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 26, 2026 | 9 months ago |
| SMA: Bearish | Jan 23, 2026 | 9 months ago |
| SMA: Bearish | Jan 23, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 21, 2026 | 9 months ago |
| RSI: Overbought | Jan 7, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 6, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Dec 19, 2025 | 10 months ago |
| SMA: Bearish | Dec 18, 2025 | 10 months ago |
| SMA: Bullish | Dec 15, 2025 | 10 months ago |
| SMA: Bearish | Dec 12, 2025 | 10 months ago |
| SMA: Bullish | Dec 11, 2025 | 10 months ago |
| SMA: Bullish | Dec 3, 2025 | 11 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 25, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 21, 2025 | 11 months ago |
| RSI: Oversold | Nov 6, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 29, 2025 | 1 year ago |
| SMA: Bearish | Oct 28, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 21, 2025 | 1 year ago |
| SMA: Bullish | Oct 16, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 7, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 26, 2025 | 1 year ago |
| SMA: Bearish | Sep 24, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 12, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| SMA: Bearish | Jul 11, 2025 | 1 year ago |
| SMA: Bullish | Jul 8, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 2, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 1, 2025 | 1 year ago |
| SMA: Bearish | Jun 13, 2025 | 1 year ago |
| SMA: Bullish | Jun 9, 2025 | 1 year ago |
| SMA: Bearish | Jun 5, 2025 | 1 year ago |
| SMA: Bullish | Jun 4, 2025 | 1 year ago |
| SMA: Bearish | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | May 27, 2025 | 1 year ago |
| MACD: Sell Signal | May 22, 2025 | 1 year ago |
| SMA: Bearish | May 21, 2025 | 1 year ago |
| SMA: Bullish | May 8, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 24, 2025 | 1 year ago |
| RSI: Oversold | Apr 16, 2025 | 1 year ago |
| RSI: Oversold | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 3, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 27, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 10, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 7, 2025 | 1 year ago |
| SMA: Bearish | Feb 6, 2025 | 1 year ago |
| SMA: Bullish | Feb 4, 2025 | 1 year ago |
| SMA: Bearish | Feb 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 28, 2025 | 1 year ago |
| SMA: Bullish | Jan 21, 2025 | 1 year ago |
| SMA: Bearish | Jan 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
Key statistics
- Market cap
- 1.01B
- Enterprise value
- 4.00B
- Trailing P/E
- 0.00
- Forward P/E
- 10.22
- PEG ratio
- 2.06
- Price / sales
- 0.38
- Price / book
- 0.57
- EPS (TTM)
- -15.43
- Beta
- 0.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -39.20%
- Revenue (TTM)
- 2.67B
- Revenue growth
- 2.80%
- Free cash flow
- 146.76M
- Total cash
- 123.40M
- Total debt
- 3.08B
- Return on equity
- -45.91%
- Shares outstanding
- 68.58M
- Short % of float
- 29.75%
- 50-day average
- 15.81
- 200-day average
- 19.67
Analyst view
Consensus: hold
- Target (low)
- 12.00
- Target (mean)
- 14.67
- Target (high)
- 20.00
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell1
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.17953.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 28, 2026 | 0.18 | — | — | — |
| Aug 6, 2026 | Jun 28, 2026 | -0.04884 | 0.13 | +0.18 | +366.18% |
| May 5, 2026 | Mar 29, 2026 | 0.37 | -0.04 | -0.41 | -110.81% |
| Feb 11, 2026 | Dec 28, 2025 | 0.43 | 0.46 | +0.03 | +6.98% |
| Nov 5, 2025 | Sep 28, 2025 | 0.51 | 0.80 | +0.29 | +56.86% |
| Aug 5, 2025 | Jun 29, 2025 | 0.00153 | 0.12 | +0.12 | +7,743.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 8, 2026 | Citigroup | main | Neutral | Neutral |
| Jul 1, 2026 | JP Morgan | main | Underweight | Underweight |
| May 7, 2026 | Jefferies | down | Buy | Hold |
| May 6, 2026 | Citigroup | main | Neutral | Neutral |
| Apr 10, 2026 | UBS | main | Neutral | Neutral |
| Feb 12, 2026 | Citigroup | main | Neutral | Neutral |
About QuidelOrtho Corporation
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- quidelortho.com
News
- Transforming Data Into Actionable Insights in the Lab
- QuidelOrtho Reports Q2 2026 Results: Full Earnings Call Transcript
- Nasdaq Gains Over 300 Points; US Employers Cut 23,000 Jobs In July
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Why Atlassian Shares Are Trading Higher By More Than 30%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- QuidelOrtho Lowers FY2026 Adj EPS Guidance from $1.80-$2.00 to $0.65-$0.90 vs $1.84 Est; Lowers FY2026 Sales Guidance from $2.700B-$2.750B to $2.520B-$2.600B vs $2.705B Est
- QuidelOrtho Q2 Adj. EPS $0.13 Beats $(0.05) Estimate, Sales $631.000M Beat $618.849M Estimate
Your note
Sign in to keep a note on QDEL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLASER BRIAN J | Chief Executive Officer | Conversion of Exercise of derivative security | May 14, 2026 | 75,722 |
| BUECHLER KENNETH F | Director | Conversion of Exercise of derivative security | Jun 4, 2026 | 110,906 |
| BUJARSKI ROBERT JOSEPH | Chief Operating Officer | Conversion of Exercise of derivative security | Oct 14, 2024 | 44,810 |
| BUSKY JOSEPH M | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 26, 2026 | 55,108 |
| HODGES MICHELLE A | Officer | Conversion of Exercise of derivative security | Feb 5, 2026 | 41,605 |
| MICHAEL EDWARD L | Director | Conversion of Exercise of derivative security | Jun 4, 2026 | 29,433 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.34% | 11,202,523 | 165.13M | Jun 29, 2026 |
| FMR, LLC | 10.74% | 7,363,696 | 108.54M | Jun 29, 2026 |
| Newtyn Management, Llc | 9.66% | 6,625,000 | 97.65M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.03% | 4,135,464 | 60.96M | Jun 29, 2026 |
| Neuberger Berman Group, LLC | 5.15% | 3,534,619 | 52.10M | Jun 29, 2026 |
| Invesco Ltd. | 5.07% | 3,473,432 | 51.20M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Capital Trust-Fidelity Value Fund | 6.38% | 4,371,779 | 64.44M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Small-Cap ETF | 6.06% | 4,153,277 | 61.22M | Jul 30, 2026 |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 4.40% | 3,020,112 | 44.52M | Apr 29, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 4.14% | 2,836,050 | 41.80M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 2,172,676 | 32.03M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.62% | 1,796,239 | 26.48M | Jun 29, 2026 |